Published in Immunol Today on January 01, 1999
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis (2007) 1.32
Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol (2006) 1.24
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ (2009) 1.13
Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci U S A (2004) 1.00
Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol (2008) 1.00
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer (2007) 0.93
Posttranslational regulation of Fas ligand function. Cell Commun Signal (2008) 0.90
Wild-derived inbred mice have a novel basis of susceptibility to polyomavirus-induced tumors. J Virol (1999) 0.90
A portrait of the Bcl-2 protein family: life, death, and the whole picture. J Clin Immunol (1999) 0.90
Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg (2007) 0.89
Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther (2007) 0.88
Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc Natl Acad Sci U S A (2002) 0.88
Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer (2000) 0.88
Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology (2002) 0.87
Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol (2001) 0.86
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol (2003) 0.86
Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res (2002) 0.85
The regulation of FasL expression during activation-induced cell death (AICD). Immunology (2001) 0.84
Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg (2004) 0.82
Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions. PLoS One (2011) 0.81
Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol (2005) 0.81
Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege. Dig Dis Sci (2000) 0.81
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL. Haematologica (2012) 0.78
The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. Proc Natl Acad Sci U S A (2001) 0.76
Circulating soluble Fas levels and risk of ovarian cancer. BMC Cancer (2003) 0.75
Immune escape mechanisms in ALCL. J Clin Pathol (2003) 0.75
Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Front Immunol (2017) 0.75
Functional impairment of dendritic cells caused by murine hepatocellular carcinoma. J Clin Immunol (2004) 0.75
Screening for the protective effect target of deproteinized extract of calf blood and its mechanisms in mice with CCl4-induced acute liver injury. PLoS One (2017) 0.75
Regulation of tumor antigen synthesis by simain virus 40 gene A. J Virol (1975) 9.93
Identification of simian virus 40 protein A. J Virol (1977) 4.93
Modification of simian virus 40 protein A. J Virol (1977) 3.79
Laparoscopic peritoneal lavage for generalized peritonitis due to perforated diverticulitis. Br J Surg (2008) 3.67
Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut (2010) 3.67
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med (1996) 3.56
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet (1994) 3.22
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol (1990) 2.98
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology (1991) 2.93
In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr (2001) 2.73
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut (2008) 2.69
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut (2003) 2.37
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
Chylothorax. Br J Surg (1997) 2.29
The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry (2012) 2.16
Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek (1999) 2.14
Insulin-dependent diabetes mellitus and coeliac disease. Lancet (1997) 2.14
Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology (1993) 2.10
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med (1991) 2.03
Change of datasheet for ketorolac. Anaesthesia (2004) 2.01
Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther (2001) 1.97
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J Appl Microbiol (1998) 1.90
Quantification of the placebo response in ulcerative colitis. Gastroenterology (1997) 1.86
Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol (1985) 1.85
Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R (1990) 1.79
The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol (1998) 1.78
Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. Proc Natl Acad Sci U S A (1989) 1.77
Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut (1999) 1.75
Pathogenesis of esophagitis in patients with gastroesophageal reflux. Surgery (1980) 1.74
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy (2010) 1.73
Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg (1982) 1.71
The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol (2000) 1.65
Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM (1997) 1.63
Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil (2008) 1.62
Thoracoscopic repair of instrumental perforation of the oesophagus: first report. Ir J Med Sci (2002) 1.59
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 1.58
Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol (1991) 1.55
A prospective comparison of laparoscopy and imaging in the staging of esophagogastric cancer before surgery. Am J Gastroenterol (1995) 1.53
Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol Cell Biol (1998) 1.52
How effective is an integrated approach to low vision rehabilitation? Two year follow up results from south Devon. Br J Ophthalmol (1995) 1.50
Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophr Res (1998) 1.45
Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med (2001) 1.45
Lack of an association between polymorphisms of the T-cell receptor alpha-chain and ulcerative colitis. Gastroenterology (1989) 1.42
Interaction of lower esophageal sphincter pressure and length of sphincter in the abdomen as determinants of gastroesophageal competence. Am J Surg (1982) 1.42
Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc (1995) 1.41
Braving the elementals in Crohn's disease. Gastroenterology (1992) 1.41
The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM (2000) 1.41
Development of a probiotic cheddar cheese containing human-derived Lactobacillus paracasei strains. Appl Environ Microbiol (1998) 1.40
Factor XIII: is it a factor in Crohn's disease? Gastroenterology (1993) 1.39
Critical appraisal of enteral nutrition as primary therapy in adults with Crohn's disease. Am J Gastroenterol (1996) 1.39
Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology (1999) 1.38
Differential depuration of poliovirus, Escherichia coli, and a coliphage by the common mussel, Mytilus edulis. Appl Environ Microbiol (1989) 1.34
Relationship of a hiatal hernia to the function of the body of the esophagus and the gastroesophageal junction. J Thorac Cardiovasc Surg (1981) 1.34
Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray drying. Appl Environ Microbiol (2000) 1.33
PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut (2002) 1.31
Direct in situ viability assessment of bacteria in probiotic dairy products using viability staining in conjunction with confocal scanning laser microscopy. Appl Environ Microbiol (2001) 1.29
Comparison of phage typing, plasmid mapping, and antibiotic resistance patterns as epidemiologic markers in a nosocomial outbreak of methicillin-resistant Staphylococcus aureus infections. Diagn Microbiol Infect Dis (1984) 1.25
Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas ligand interactions. Infect Immun (2000) 1.23
Immunologic mechanisms in intestinal diseases. Ann Intern Med (1987) 1.23
Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet (1996) 1.23
An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol (1999) 1.23
Antibiotic susceptibility of potentially probiotic Lactobacillus species. J Food Prot (1998) 1.23
Shedding of enteric coronavirus in adult cattle. Am J Vet Res (1987) 1.22
Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins. J Infect Dis (1983) 1.20
Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol (1998) 1.18
Epstein-Barr virus SM protein. Virology (1994) 1.18
Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res (1995) 1.18